177Lu-DOTATOC Clinical Trials
3 recruitingDrug
Early Phase 11Phase 21Phase 31
Showing 1–3 of 3 trials
Recruiting
Phase 3
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Neuroendocrine Tumors
Lund University Hospital300 enrolled4 locationsNCT05387603
Recruiting
Phase 2
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Neuroendocrine TumorsParagangliomaPheochromocytoma
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS100 enrolled2 locationsNCT06045260
Recruiting
Early Phase 1
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland16 enrolled1 locationNCT05359146